Efectividad del tratamiento con la Asociación de Dutasteride más Tamsulosina en pacientes con hiperplasia prostática benigna en el Hospital Naval de Guayaquil (HOSNAG) durante el período de enero de 2016 hasta marzo de 2019.

Abstract

Benign prostatic hyperplasia (BPH) is a progressive pathology in mainly older males(1) with an excessive, not malignant increase in the prostate gland(2) which produces symptoms of the lower urinary tract affecting the quality of life.(3) Smooth muscle proliferation of the prostate gland, caused by the activation of metabolite of the male hormone 5 - Dihydroxytestosterone (DHT) is considered the main cause.(4) Within the obstructive symptomatology we have: weak urine jet, difficulty initiating urination, polyaquiuria, tenesmus, Nocturia, incomplete emptying, loss of urine, emergency incontinence and complete urinary retention.(3) The first line medication will depend on the treating physician, considering the adverse effects of the medication and patient preferences as this is often a problem for adherence to treatment.(5) Materials and methods: A series case study, observational and retrospective. The information was obtained from the medical records and the scale of the IPSS of patients with diagnosis of HPB of the Naval Hospital of Guayaquil. Results: The analysis was carried out on 200 patients diagnosed with BPH who were screened after 6 months of the administration of dutasteride plus tamsulosine. In the first consultation, 1% of patients presented an IPSS value that could be interpreted as mild. Subsequently, at 6 months, 29% of patients decreased their IPSS symptoms and score. Conclusions: After the treatment of dutasteride more tamsulosine significant clinical improvement is evidenced.